KETOCONAZOLE 1% SHAMPOO Rx-TO-OTC SWITCH APPLICATION TO BE REVIEWED
This article was originally published in The Tan Sheet
Executive Summary
KETOCONAZOLE 1% SHAMPOO Rx-TO-OTC SWITCH APPLICATION TO BE REVIEWED at a Feb. 16 joint meeting of FDA's Nonprescription Drugs Advisory Committee and Dermatologic Drugs Advisory Committee, according to a notice in the Jan. 27 Federal Register. Johnson & Johnson Consumer Products' Rx-to-OTC switch NDA (20-310) covers the use of the ketoconazole 1% formulation for the treatment of dandruff. The Feb. 16 advisory committee meeting will begin at 1 p.m. in Conference Rooms G through J at FDA's Parklawn Building, 5600 Fishers Lane, Rockville, Md.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: